Glioblastoma Pipeline Drugs Analysis Report, 2024 Updates: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | InovioPharma, Pfizer, Roche, ACADIA Pharma, BioNTech, Oncotelic

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Glioblastoma pipeline constitutes 195+ key companies continuously working towards developing 210+ Glioblastoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Glioblastoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

"Glioblastoma Pipeline Insight, 2024 [https://www.delveinsight.com/sample-request/glioblastoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Glioblastoma Market.

Some of the key takeaways from the Glioblastoma Pipeline Report:

* Companies across the globe are diligently working toward developing novel Glioblastoma treatment therapies with a considerable amount of success over the years.
* Glioblastoma companies working in the treatment market are J INTS BIO, Curtana Pharmaceuticals, Prelude Therapeutics, OX2 Therapeutics, Polaris Group, Crimson Biopharm, CNS Pharmaceuticals, MimiVax, Berg, LLC, Ascletis, Denovo Biopharma, Celgene Corporation, and others, are developing therapies for the Glioblastoma treatment

* Emerging Glioblastoma therapies in the different phases of clinical trials are- JIN 001, CT 179, PRT3645, CD200AR L, ADI-PEG 20, CM93, Berubicin, SurVaxM, BPM31510, ASC40, Enzastaurin, Marizomib, and others are expected to have a significant impact on the Glioblastoma market in the coming years.
* In November 2023, The collaboration between the Global Coalition for Adaptive Research (GCAR) and the Cure Brain Cancer Foundation (CBCF) has led to the initiation of the Glioblastoma Adaptive Global Innovative Learning Environment (GBM AGILE) trial in Australia.
* In June 2023, Chimeric Therapeutics initiated a Phase 1B clinical study targeting individuals with recurrent and/or progressive glioblastoma multiforme (GBM). The trial aims to evaluate the safety and effectiveness of CHM 1101, their pioneering CLTX CAR T cell therapy.
* In August 2022, Northwest Biotherapeutics obtained endorsement from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) for its Pediatric Investigation Plan (PIP). Securing PIP development, regulatory assessment, and approval is essential before seeking authorization for new medications, like DCVax-L, targeting adult patients.
* Among the up-and-coming treatments for glioblastoma, Trabedersen is currently advancing through Phase III clinical development, while Selinexor is undergoing Phase II trials.
* Among the early-stage pipeline treatments for glioblastoma, AZD1390 is currently in Phase I clinical trials.

Glioblastoma Overview

Glioblastoma, also known as glioblastoma multiforme (GBM), is a type of malignant brain tumor that arises from astrocytes, a type of supportive cells in the brain. It is the most aggressive and common form of primary brain cancer in adults. Glioblastomas are highly infiltrative tumors, meaning they spread rapidly and invade surrounding brain tissue, making complete surgical removal difficult.

Get a Free Sample PDF Report to know more about Glioblastoma Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/glioblastoma-pipeline-insight [https://www.delveinsight.com/report-store/glioblastoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Emerging Glioblastoma Drugs Under Different Phases of Clinical Development Include:

* JIN 001: J INTS BIO
* CT 179: Curtana Pharmaceuticals
* PRT3645: Prelude Therapeutics
* CD200AR L: OX2 Therapeutics
* ADI-PEG 20: Polaris Group
* CM93: Crimson Biopharm
* Berubicin: CNS Pharmaceuticals
* SurVaxM: MimiVax
* BPM31510: Berg, LLC
* ASC40: Ascletis
* Enzastaurin: Denovo Biopharma
* Marizomib: Celgene Corporation

Glioblastoma Route of Administration

Glioblastoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

* Oral
* Parenteral
* Intravenous
* Subcutaneous
* Topical

Glioblastoma Molecule Type

Glioblastoma Products have been categorized under various Molecule types, such as

* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy

Glioblastoma Pipeline Therapeutics Assessment

* Glioblastoma Assessment by Product Type
* Glioblastoma By Stage and Product Type
* Glioblastoma Assessment by Route of Administration
* Glioblastoma By Stage and Route of Administration
* Glioblastoma Assessment by Molecule Type
* Glioblastoma by Stage and Molecule Type

DelveInsight's Glioblastoma Report covers around 210+ products under different phases of clinical development like

* Late-stage products (Phase III)
* Mid-stage products (Phase II)
* Early-stage product (Phase I)
* Pre-clinical and Discovery stage candidates
* Discontinued & Inactive candidates
* Route of Administration

Further Glioblastoma product details are provided in the report. Download the Glioblastoma pipeline report to learn more about the emerging Glioblastoma therapies [https://www.delveinsight.com/sample-request/glioblastoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key companies in the Glioblastoma Therapeutics Market include:

Key companies developing therapies for Glioblastoma are - Array Biopharma, AstraZeneca, Doule bond Pharmaceuticals, Philogen, Immatics N.V, BioNTech, InovioPharma, Noxxon Pharma, Celgene Corporation, Karyo Pharma, Neugate Theranostics, Novartis, Orphelia Pharma, Merck, Acerta Pharma, Genenta Science, CNS Pharmaceutical, Pfizer, Roche, Oncotelic Therapeutics, Autotelic Therapeutics, ACADIA Pharmaceuticals, Mayo Clinic, Cytogel, Xgene Pharmaceutical, Ascletis, 3-V Biosciences, Yumanity Therapeutics, and others.

Glioblastoma Pipeline Analysis:

The Glioblastoma pipeline report provides insights into

* The report provides detailed insights about companies that are developing therapies for the treatment of Glioblastoma with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Glioblastoma Treatment.
* Glioblastoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Glioblastoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Glioblastoma market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Glioblastoma drugs and therapies [https://www.delveinsight.com/sample-request/glioblastoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Glioblastoma Pipeline Market Drivers

* Rising incidence of Glioblastoma multiforme, improving Healthcare Infrastructure, demand for New and Effective Drugs are some of the important factors that are fueling the Glioblastoma Market.

Glioblastoma Pipeline Market Barriers

* However, aggressive nature of GBM and the complexity of targeting the central nervous system, the current standard of care for patients with newly diagnosed glioblastoma has limited effectiveness and a second line has not been established and other factors are creating obstacles in the Glioblastoma Market growth.

Scope of Glioblastoma Pipeline Drug Insight

* Coverage: Global
* Key Glioblastoma Companies: J INTS BIO, Curtana Pharmaceuticals, Prelude Therapeutics, OX2 Therapeutics, Polaris Group, Crimson Biopharm, CNS Pharmaceuticals, MimiVax, Berg, LLC, Ascletis, Denovo Biopharma, Celgene Corporation, and others
* Key Glioblastoma Therapies: JIN 001, CT 179, PRT3645, CD200AR L, ADI-PEG 20, CM93, Berubicin, SurVaxM, BPM31510, ASC40, Enzastaurin, Marizomib, and others
* Glioblastoma Therapeutic Assessment: Glioblastoma current marketed and Glioblastoma emerging therapies
* Glioblastoma Market Dynamics: Glioblastoma market drivers and Glioblastoma market barriers

Request for Sample PDF Report for Glioblastoma Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/glioblastoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Glioblastoma Report Introduction

2. Glioblastoma Executive Summary

3. Glioblastoma Overview

4. Glioblastoma- Analytical Perspective In-depth Commercial Assessment

5. Glioblastoma Pipeline Therapeutics

6. Glioblastoma Late Stage Products (Phase II/III)

7. Glioblastoma Mid Stage Products (Phase II)

8. Glioblastoma Early Stage Products (Phase I)

9. Glioblastoma Preclinical Stage Products

10. Glioblastoma Therapeutics Assessment

11. Glioblastoma Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Glioblastoma Key Companies

14. Glioblastoma Key Products

15. Glioblastoma Unmet Needs

16 . Glioblastoma Market Drivers and Barriers

17. Glioblastoma Future Perspectives and Conclusion

18. Glioblastoma Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=glioblastoma-pipeline-drugs-analysis-report-2024-updates-fda-approvals-clinical-trials-therapies-moa-roa-by-delveinsight-inoviopharma-pfizer-roche-acadia-pharma-biontech-oncotelic]
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.